Program
AGN-193408
A development code. Also written as “AGN-193408 SR”.
In AbbVie's pipeline, PGF2 alpha receptor
. Its studies are mostly in Glaucoma, Open-Angle, led by AbbVie.
Furthest: phase 2, since Jul 31, 20201 company-led study, 1 open or runningNext primary completion: Apr 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 11 open or running | phase 2since Jul 31, 2020 | Jul 31, 2020 | Apr 2029phase 2 · NCT04499248 |
- Named in AbbVie’s own pipeline as
AGN-193408
, phase 2, as of Jul 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 31, 2020First study: phase 2 study in Glaucoma, Open-AngleFirst studyNCT04499248 · 100 enrolled · United States, Japan
Ahead
- Apr 2029Primary completion: phase 2 study in Glaucoma, Open-AngleNCT04499248
TargetBeta
“PGF2 alpha receptor”the company's pipeline, read by Claude · source
Other programs on PTGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Travoprostrule | Alcon | phase 4 | 67 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04499248Glaucoma, Open-Angle · United States, Japan | 2 | Active, not recruiting | Apr 2029 | 100 |
How it is read
Names in the registry
- “AGN-193408 SR”, 2 entries
Codes read as this program: AGN193408.
Conditions, from the studies’ own filings
- Glaucoma, Open-Angle, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.